NCT05252923

Endothelial Protection in Convalescent COVID-19 Patients

Endothelial Protection in Convalescent COVID-19 Patients. The Effect of Sulodexide on Serum Levels of Biomarkers for Endothelial Dysfunction. A Pilot Prospective, Randomized, Open-label, Investigator-initiated Trial.

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Pirogov Russian National Research Medical University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This pilot open-label randomized controlled trial aims to assess if treatment with sulodexide may improve the endothelial status and inflammatory response in post-COVID-19 patients. Survived inpatients with severe-to-critical COVID-19 within 14 days after discharge are randomized to receive sulodexide 250 LSU 1 oral capsule twice daily or no treatment for 8 weeks. Biomarkers of endothelial dysfunction, inflammation, and prothrombotic changes are assessed at 0, 4, and 8 weeks. The hypothesis is that affected endothelial function, pro-inflammatory, and pro-thrombotic changes could be improved with sulodexide treatment in convalescent COVID-19 patients who suffered a severe-to-critical clinical presentation and have chronic comorbidities of high risk for endothelial dysfunction.

Conditions

• Endothelial Dysfunction
• Inflammation
• Thrombosis
• COVID-19

Interventions

Type	Name	Description
DRUG	Sulodexide	Sulodexide 250 LSU 1 oral capsule twice daily for 8 weeks

Timeline

• Start date: 2022-04-01
• Primary completion: 2022-09-01
• Completion: 2022-12-31
• First posted: 2022-02-23
• Last updated: 2025-06-13

Locations

1 site across 1 country: Russia